Aurinia Pharmaceuticals Inc (AUPH)

[Zeppo]

Most posters here are a bit frustrated whether they're newbies or oldies. Break down the whole situation, and what do we have? We have a company that, so far, has been GIA. We can't count the first quarter in the revenue argument, because almost 1/3 of the quarter was gone before we got word that Lupkynis had been approved. Revenues of six and fourteen million dollars were reported during the next two quarters with a projection of 20-25 million for the 4th quarter. All numbers were accomplished while GIA. Preliminary A-2 reports emerge, and they're positive. I am wondering if a positive report for A-2 and A-3 will eliminate the "black box". We know that AUPH has several other indications for this product. All of a sudden, out of the clear blue, we get a rumor that BMY and a half dozen other companies are interested in AUPH. GLX denies interest, even though it has a "last minute approved", but inferior product. Takeda, Otsuka, Pfizer, and Astra are mentioned with analysts speculating that a merger with BMY or PFE would make sense. All is quiet until we hear the uproar about the "shelf registration". Background on PG tells us he has used the "shelf registration" in a "strategic" manner in the past. So we wait. My own most humble opinion points to the coincidence of the shelf registration being created while the media has the company in talks with, potentially, several members of big pharma. So......is it all smoke and mirrors or is the company in the middle of serious price negotiations and potential partnerships? MHO points to the latter.